Article
Can I use DOAC in a patient with renal disease?
February 3, 2022
Case A 76-year-old man is diagnosed with non-valvular atrial fibrillation. His comorbid conditions are hypertension, diabetes complicated by neuropathy, and chronic kidney disease stage 3. His...
![1]()
News
Apixaban a reasonable alternative to warfarin in patients with severe renal impairment
December 9, 2021
Is apixaban a safe alternative to warfarin in patients with severe renal impairment?
![1]()
News
Timing of initiation of renal-replacement therapy in acute kidney injury
December 8, 2021
In critically ill patients, does early renal-replacement therapy (RRT), compared with standard therapy, improve death from any cause at 90 days?
![1]()
News
Comparing the efficacy and safety of common SIADH treatments
November 24, 2021
Is fluid restriction or the addition of furosemide with or without NaCl supplementation more efficacious for the treatment of hyponatremia caused by syndrome of inappropriate antidiuretic hormone (SIADH)?
News
Acute urinary retention tied to increased risk of certain cancers
November 24, 2021
“Admission with a first-time acute urinary retention could be an opportunity to diagnose an occult cancer.”
![1]()
News
What makes a urinary tract infection complicated?
November 22, 2021
There are multiple interpretations of complicated UTIs.
![1]()
News
Timing of renal-replacement therapy for AKI in the ICU
November 19, 2021
Does earlier initiation of renal-replacement therapy (RRT) improve mortality in the ICU?
News
Advanced CKD doesn’t derail empagliflozin in EMPEROR-preserved
November 19, 2021
Study shows empagliflozin led to a consistent, significant relative risk reduction compared with placebo in the primary endpoint.
News
Fluoroquinolones linked to sudden death risk for those on hemodialysis
October 25, 2021
Most patients undergoing hemodialysis have a least one risk factor for drug-induced QT interval prolongation.
![1]()
News
ACE-I or ARB therapy in patients with low eGFR
August 26, 2021
Is it safe to continue angiotensin-converting enzyme inhibitor (ACE-I) or angiotensin II receptor blocker (ARB) therapy in patients whose estimated glomerular filtration rate (eGFR) has decreased to below 30 mL/min per 1.73 m2?
